Oxford BioTherapeutics has lined up another big pharma partner for its drug discovery platform, signing a $1bn deal with oncology giant Roche.

Oxford BioTherapeutics has lined up another big pharma partner for its drug discovery platform, signing a $1bn deal with oncology giant Roche.

🚀 Roche has recently entered into a collaboration with Oxford BioTherapeutics (OBT) to identify novel targets for antibody-based cancer therapies. The partnership includes an upfront payment of ...

(MENAFN- EIN Presswire) Partnership to accelerate development of Novel Small Extracellular Vesicle CNS Drug Delivery Platform and enhance Interactome Biotherapeutics' Pipeline OXFORD , UNITED ...

Shareholders approved all proposals of the Board of Directors Severin Schwan was re-elected as Chairman of the Board of Directors; all other Board members standing for election were confirmed38th cons ...

SAN DIEGO, March 24, 2025 (GLOBE NEWSWIRE) -- Artiva Biotherapeutics, Inc. (Nasdaq: ARTV) (Artiva), a clinical-stage biotechnology company whose mission is to develop effective, safe, and ...

REDWOOD CITY, Calif. (AP) — REDWOOD CITY, Calif. (AP) — Bolt Biotherapeutics Inc. (BOLT) on Monday reported a loss of $15.9 million in its fourth quarter. The Redwood City, California-based ...

Investing.com -- Shares of Artiva Biotherapeutics Inc (NASDAQ:ARTV) climbed 2.5% as the company received positive comments from H.C. Wainwright analyst Edward White. The uptick in stock price ...

REDWOOD CITY, Calif., March 25, 2025 (GLOBE NEWSWIRE) -- Bolt Biotherapeutics (Nasdaq: BOLT), a clinical-stage biopharmaceutical company developing novel immunotherapies for the treatment of cancer, ...

Such forward-looking statements include, without limitation, statements regarding: expectations of Artiva Biotherapeutics, Inc. (the "Company”) regarding the potential benefits, accessibility, ...

(MENAFN- GlobeNewsWire - Nasdaq) Antibody drug conjugates have emerged as a potential option to selectively eliminate the tumor population, with minimal side effects. Till date, several clinical ...